Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 5th Preview)
-
GLP-1 competitive dynamics and pipeline pressure
Eli Lilly’s newest oral obesity therapy, Foundayo, is showing early sales disappointment even as the company’s injectable tirzepatide franchises continue to surge. Lilly reported $98 million in second-quarter sales for Foundayo and kept focus on rapid growth in Mounjaro and Zepbound, driving a lift in full-year revenue guidance. Novo Nordisk, meanwhile, took the opposite investor hit after earnings, reflecting the widening competitive gap in cardiometabolic portfolios. Novo’s Wegovy pill posted second-quarter sales short of expectations, while injectables remain central to its obesity strategy as it simultaneously pushes next-generation candidates. Together, the quarter-by-quarter results underscore how quickly the market is recalibrating around oral and injectable incretin performance—and how trial readouts shape near-term capital allocation for obesity drug developers.
-
Novo pipeline setback and CEO response on innovation
Novo Nordisk’s CEO Maziar Mike Doustdar told investors on an earnings call that innovation is a matter of survival after a run of R&D setbacks. He pointed to “really good early signs” from early-stage pipeline products while avoiding further detail on assets that are still in development. The comments followed late-stage trial disappointments for Novo, including ziltivekimab’s Phase 3 ZEUS failure in atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. Novo also faces competitive pressure from Lilly’s obesity pipeline after head-to-head trial results raised doubts around Novo’s next-generation obesity candidate CagriSema. The episode highlights how Novo is managing investor expectations while attempting to re-center the obesity and cardiometabolic narrative on earlier-stage programs ahead of future clinical readouts.
-
HIV prevention revenue milestone and scrutiny of durability
Gilead reported its first-quarterly PrEP milestone, with Yeztugo exceeding $1 billion in quarterly sales for the HIV prevention franchise. In the second quarter of 2026, PrEP sales reached $1.03 billion, with daily Descovy contributing $801 million, while Yeztugo generated $232 million. Despite the revenue beat, analysts are probing whether Yeztugo’s long-term growth can match the early adoption curve. Gilead kept its full-year Yeztugo forecast around $1 billion, and Leerink highlighted both favorable persistence early on and upcoming competitive risk from alternative formulations. The durability question also intersects with a future weekly oral lenacapavir-based PrEP option that is under FDA review, setting up a potential next phase of competition in a fragmented U.S. PrEP market.
-
Court limits ‘duty to innovate’ claims against drugmakers
The California Supreme Court ruled in favor of Gilead, dismissing thousands of negligence claims over tenofivor-based HIV medicines and setting a precedent limiting “duty to innovate” theories. The court, in a 6-1 decision, rejected arguments that patients would have switched sooner to safer tenofovir alafenamide (TAF) products if Gilead had not delayed. In its majority opinion, Justice Joshua Groben said imposing such liability would create “extraordinary burdens,” risk “distorting research priorities,” and potentially chill pharmaceutical innovation. The ruling ends years of litigation over older and newer Gilead PrEP and HIV treatments, reaffirming that liability for injuries caused by nondefective drugs cannot be expanded into a broad mandate to deliver alternative formulations faster.
-
AstraZeneca-Bristol Myers merger rumors cooled by Reuters report
A Reuters report said AstraZeneca and Bristol Myers Squibb are not having ongoing discussions about a potential merger, undercutting recent media coverage of talks. A senior source told Reuters there is “no deal” and “no discussions,” following Financial Times reporting that AstraZeneca was in talks. Investor reaction reflected the uncertainty: AstraZeneca’s stock slid after the initial rumor, then partially rebounded after Reuters’ clarification. The companies’ combined scale would have created a pharmaceutical group valued near $400 billion, but analysts warned of antitrust scrutiny and R&D disruption. The episode emphasizes how fast market pricing is reacting to large-cap M&A speculation and how quickly that sentiment can pivot on confirmation or denial.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.